CA1340084C - Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales - Google Patents

Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales

Info

Publication number: CA1340084C
Authority: CA; Canada
Prior art keywords: compound; prophylaxis; treatment; medicament; manufacture
Prior art date: 1987-11-05
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

CA000616926A

Other languages

English (en)

Inventor

Thomas A. Krenitsky

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Wellcome Foundation Ltd

Original Assignee

Wellcome Foundation Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-11-05

Filing date

1994-08-25

Publication date

1998-10-13

1987-11-05 Priority claimed from GB878725939A external-priority patent/GB8725939D0/en

1994-08-25 Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd

1994-08-25 Priority to CA000616926A priority Critical patent/CA1340084C/fr

1998-10-13 Application granted granted Critical

1998-10-13 Publication of CA1340084C publication Critical patent/CA1340084C/fr

2008-08-12 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

230000000840 anti-viral effect Effects 0.000 title claims description 9
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 title description 28
150000002148 esters Chemical class 0.000 title description 6
238000011282 treatment Methods 0.000 claims abstract description 26
238000011321 prophylaxis Methods 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 22
208000029433 Herpesviridae infectious disease Diseases 0.000 claims abstract description 3
150000001875 compounds Chemical class 0.000 claims description 73
239000004480 active ingredient Substances 0.000 claims description 51
239000003814 drug Substances 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 12
238000004519 manufacturing process Methods 0.000 claims description 12
-1 2-Amino-1,6-dihydro-6-oxo-9H-purin-9-yl Chemical group 0.000 claims description 10
239000002253 acid Substances 0.000 claims description 9
239000008194 pharmaceutical composition Substances 0.000 claims description 8
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 5
230000009385 viral infection Effects 0.000 claims description 5
208000031886 HIV Infections Diseases 0.000 claims description 4
208000009889 Herpes Simplex Diseases 0.000 claims description 3
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 3
ICPWNTVICOHCML-BQBZGAKWSA-N ethyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound CCOC(=O)[C@@H](N)[C@@H](C)CC ICPWNTVICOHCML-BQBZGAKWSA-N 0.000 claims description 3
HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 claims description 3
229960002555 zidovudine Drugs 0.000 claims description 3
QISOBCMNUJQOJU-UHFFFAOYSA-N 4-bromo-1h-pyrazole-5-carboxylic acid Chemical compound OC(=O)C=1NN=CC=1Br QISOBCMNUJQOJU-UHFFFAOYSA-N 0.000 claims description 2
PXRKCOCTEMYUEG-UHFFFAOYSA-N 5-aminoisoindole-1,3-dione Chemical compound NC1=CC=C2C(=O)NC(=O)C2=C1 PXRKCOCTEMYUEG-UHFFFAOYSA-N 0.000 claims description 2
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 2
208000007514 Herpes zoster Diseases 0.000 claims description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
208000036142 Viral infection Diseases 0.000 claims description 2
208000002672 hepatitis B Diseases 0.000 claims description 2
208000015181 infectious disease Diseases 0.000 claims description 2
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims 3
208000037357 HIV infectious disease Diseases 0.000 claims 2
208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 2
WTBHYMWEURPQQT-OZZZDHQUSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl (2s,3s)-2-amino-3-methylpentanoate;hydrochloride Chemical compound Cl.N1=C(N)NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)[C@@H](C)CC)C=N2 WTBHYMWEURPQQT-OZZZDHQUSA-N 0.000 claims 1
206010011831 Cytomegalovirus infection Diseases 0.000 claims 1
206010015108 Epstein-Barr virus infection Diseases 0.000 claims 1
241000700588 Human alphaherpesvirus 1 Species 0.000 claims 1
208000005181 Varicella Zoster Virus Infection Diseases 0.000 claims 1
230000000798 anti-retroviral effect Effects 0.000 claims 1
208000010531 varicella zoster infection Diseases 0.000 claims 1
DYTMGBXTNHPPNK-IUCAKERBSA-N 2-[(2-amino-6-oxo-3h-purin-9-yl)methoxy]ethyl (2s,3s)-2-amino-3-methylpentanoate Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)[C@@H](C)CC)C=N2 DYTMGBXTNHPPNK-IUCAKERBSA-N 0.000 abstract 1
239000000203 mixture Substances 0.000 description 53
238000009472 formulation Methods 0.000 description 39
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
229960004150 aciclovir Drugs 0.000 description 24
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 20
238000000034 method Methods 0.000 description 17
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
239000003826 tablet Substances 0.000 description 14
239000004615 ingredient Substances 0.000 description 12
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 11
238000006243 chemical reaction Methods 0.000 description 11
239000007788 liquid Substances 0.000 description 11
235000019359 magnesium stearate Nutrition 0.000 description 10
239000000243 solution Substances 0.000 description 10
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
239000000460 chlorine Substances 0.000 description 8
239000008101 lactose Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
125000003277 amino group Chemical group 0.000 description 7
230000008569 process Effects 0.000 description 7
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
241001465754 Metazoa Species 0.000 description 6
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
229920000036 polyvinylpyrrolidone Polymers 0.000 description 6
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 6
229940069328 povidone Drugs 0.000 description 6
239000000843 powder Substances 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 5
239000000969 carrier Substances 0.000 description 5
201000010099 disease Diseases 0.000 description 5
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
239000008187 granular material Substances 0.000 description 5
125000002887 hydroxy group Chemical group [H]O* 0.000 description 5
239000007787 solid Substances 0.000 description 5
VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
125000002252 acyl group Chemical group 0.000 description 4
229940024606 amino acid Drugs 0.000 description 4
235000001014 amino acid Nutrition 0.000 description 4
125000004429 atom Chemical group 0.000 description 4
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
230000037396 body weight Effects 0.000 description 4
238000007906 compression Methods 0.000 description 4
230000006835 compression Effects 0.000 description 4
238000013270 controlled release Methods 0.000 description 4
239000006071 cream Substances 0.000 description 4
235000011187 glycerol Nutrition 0.000 description 4
229960000310 isoleucine Drugs 0.000 description 4
125000006239 protecting group Chemical group 0.000 description 4
239000000829 suppository Substances 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
229930182844 L-isoleucine Natural products 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
238000010521 absorption reaction Methods 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 description 3
239000007963 capsule composition Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
238000011049 filling Methods 0.000 description 3
239000000796 flavoring agent Substances 0.000 description 3
239000007903 gelatin capsule Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000007327 hydrogenolysis reaction Methods 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000002245 particle Substances 0.000 description 3
239000006072 paste Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
238000011084 recovery Methods 0.000 description 3
229940080313 sodium starch Drugs 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
230000000699 topical effect Effects 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
JSHXJPFZKBRLFU-JQWIXIFHSA-N (2s,3s)-3-methyl-2-(phenylmethoxycarbonylamino)pentanoic acid Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)OCC1=CC=CC=C1 JSHXJPFZKBRLFU-JQWIXIFHSA-N 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
CTPDSKVQLSDPLC-UHFFFAOYSA-N 2-(oxolan-2-ylmethoxy)ethanol Chemical compound OCCOCC1CCCO1 CTPDSKVQLSDPLC-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
235000003911 Arachis Nutrition 0.000 description 2
244000105624 Arachis hypogaea Species 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
IVRMZWNICZWHMI-UHFFFAOYSA-N Azide Chemical compound [N-]=[N+]=[N-] IVRMZWNICZWHMI-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
241000701027 Human herpesvirus 6 Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
241000700159 Rattus Species 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
125000003435 aroyl group Chemical group 0.000 description 2
125000005002 aryl methyl group Chemical group 0.000 description 2
125000005161 aryl oxy carbonyl group Chemical group 0.000 description 2
235000019445 benzyl alcohol Nutrition 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
230000003197 catalytic effect Effects 0.000 description 2
238000009903 catalytic hydrogenation reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
239000007979 citrate buffer Substances 0.000 description 2
238000007907 direct compression Methods 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
QQGRWNMNWONMOO-LEUCUCNGSA-N ethyl (2s,3s)-2-amino-3-methylpentanoate;hydron;chloride Chemical compound Cl.CCOC(=O)[C@@H](N)[C@@H](C)CC QQGRWNMNWONMOO-LEUCUCNGSA-N 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000005843 halogen group Chemical group 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000000543 intermediate Substances 0.000 description 2
238000007913 intrathecal administration Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
235000010445 lecithin Nutrition 0.000 description 2
239000000787 lecithin Substances 0.000 description 2
229940067606 lecithin Drugs 0.000 description 2
239000000463 material Substances 0.000 description 2
238000013160 medical therapy Methods 0.000 description 2
239000000155 melt Substances 0.000 description 2
238000000465 moulding Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
235000010234 sodium benzoate Nutrition 0.000 description 2
239000004299 sodium benzoate Substances 0.000 description 2
238000003797 solvolysis reaction Methods 0.000 description 2
229940032147 starch Drugs 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011200 topical administration Methods 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
239000008215 water for injection Substances 0.000 description 2
GBKVTQSWZCBVSL-FHAQVOQBSA-N (2s,3s)-2-amino-3-methylpentanoic acid;hydrochloride Chemical compound Cl.CC[C@H](C)[C@H](N)C(O)=O GBKVTQSWZCBVSL-FHAQVOQBSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
102100025854 Acyl-coenzyme A thioesterase 1 Human genes 0.000 description 1
101710175445 Acyl-coenzyme A thioesterase 1 Proteins 0.000 description 1
102000055025 Adenosine deaminases Human genes 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
239000004358 Butane-1, 3-diol Substances 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
241000701022 Cytomegalovirus Species 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
241000450599 DNA viruses Species 0.000 description 1
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
229910004373 HOAc Inorganic materials 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
HOKDBMAJZXIPGC-UHFFFAOYSA-N Mequitazine Chemical compound C12=CC=CC=C2SC2=CC=CC=C2N1CC1C(CC2)CCN2C1 HOKDBMAJZXIPGC-UHFFFAOYSA-N 0.000 description 1
229920003094 Methocel™ K4M Polymers 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001529936 Murinae Species 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
208000005074 Retroviridae Infections Diseases 0.000 description 1
241000700584 Simplexvirus Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
241000700605 Viruses Species 0.000 description 1
208000000260 Warts Diseases 0.000 description 1
150000008065 acid anhydrides Chemical class 0.000 description 1
125000004423 acyloxy group Chemical group 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
150000001294 alanine derivatives Chemical class 0.000 description 1
238000006136 alcoholysis reaction Methods 0.000 description 1
GZCGUPFRVQAUEE-SLPGGIOYSA-N aldehydo-D-glucose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O GZCGUPFRVQAUEE-SLPGGIOYSA-N 0.000 description 1
125000005103 alkyl silyl group Chemical group 0.000 description 1
125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
125000004414 alkyl thio group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
229940089206 anhydrous dextrose Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000003125 aqueous solvent Substances 0.000 description 1
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
244000309464 bull Species 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
238000004422 calculation algorithm Methods 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000001589 carboacyl group Chemical group 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000004590 computer program Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
239000007822 coupling agent Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
231100000223 dermal penetration Toxicity 0.000 description 1
IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
229960001760 dimethyl sulfoxide Drugs 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000007904 elastic gelatin capsule Substances 0.000 description 1
238000010828 elution Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000005886 esterification reaction Methods 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000006052 feed supplement Substances 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
150000002333 glycines Chemical class 0.000 description 1
230000009036 growth inhibition Effects 0.000 description 1
150000004820 halides Chemical class 0.000 description 1
229940116364 hard fat Drugs 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
150000003840 hydrochlorides Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000008309 hydrophilic cream Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
239000007972 injectable composition Substances 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
DWKPPFQULDPWHX-VKHMYHEASA-N l-alanyl ester Chemical compound COC(=O)[C@H](C)N DWKPPFQULDPWHX-VKHMYHEASA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
238000011670 long-evans rat Methods 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003511 macrogol Drugs 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
GRWIABMEEKERFV-UHFFFAOYSA-N methanol;oxolane Chemical compound OC.C1CCOC1 GRWIABMEEKERFV-UHFFFAOYSA-N 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000002808 molecular sieve Substances 0.000 description 1
239000002324 mouth wash Substances 0.000 description 1
TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
229940097496 nasal spray Drugs 0.000 description 1
239000007922 nasal spray Substances 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000003883 ointment base Substances 0.000 description 1
229940054534 ophthalmic solution Drugs 0.000 description 1
239000002997 ophthalmic solution Substances 0.000 description 1
208000003154 papilloma Diseases 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000035515 penetration Effects 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
239000012071 phase Substances 0.000 description 1
238000002962 plaque-reduction assay Methods 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
238000002360 preparation method Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000002510 pyrogen Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
229960001860 salicylate Drugs 0.000 description 1
238000007493 shaping process Methods 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
239000002356 single layer Substances 0.000 description 1
201000010153 skin papilloma Diseases 0.000 description 1
238000009491 slugging Methods 0.000 description 1
URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000002798 spectrophotometry method Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
208000025889 stromal keratitis Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004906 thiomersal Drugs 0.000 description 1
229940100611 topical cream Drugs 0.000 description 1
229940100615 topical ointment Drugs 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
231100000048 toxicity data Toxicity 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000004665 trialkylsilyl group Chemical group 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
210000003501 vero cell Anatomy 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA000616926A 1987-11-05 1994-08-25 Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales Expired - Lifetime CA1340084C (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000616926A CA1340084C (fr)	1987-11-05	1994-08-25	Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
GB878725939A GB8725939D0 (en)	1987-11-05	1987-11-05	Therapeutic compounds
GB8725939		1987-11-05
CA5746132		1988-08-12
CA000616926A CA1340084C (fr)	1987-11-05	1994-08-25	Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales

Related Parent Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000574613A Division CA1340083C (fr)	1987-08-15	1988-08-12	Esters de 9-(2-hydroxyethoxymethyl)guanine possedant des proprietes antivirales

Publications (1)

Publication Number	Publication Date
CA1340084C true CA1340084C (fr)	1998-10-13

Family

ID=25682899

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000616926A Expired - Lifetime CA1340084C (fr)	1987-11-05	1994-08-25	Esters de 9-(hydroxethoxymethyl)guanine possedant des proprietes antivirales

Country Status (1)

Country	Link
CA (1)	CA1340084C (fr)

1994
- 1994-08-25 CA CA000616926A patent/CA1340084C/fr not_active Expired - Lifetime

Legal Events

Date	Code	Title	Description
2015-12-15	MKEX	Expiry	Effective date: 20151013

Publication	Publication Date	Title
EP0596542B1 (fr)	1996-05-29	Nucléosides thérapeutiques
US4957924A (en)	1990-09-18	Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof
EP0072027B1 (fr)	1988-05-18	Composés antiviraux
US4548819A (en)	1985-10-22	Derivatives of 9-(2-hydroxyethoxymethyl) guanine
US5043339A (en)	1991-08-27	Antiviral compounds
US6083953A (en)	2000-07-04	2- (2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3- propanediol derivative
EP0158847B1 (fr)	1988-04-20	Dérivés de purine antiviraux
CA1266862A (fr)	1990-03-20	Composes antiviraux
US5061708A (en)	1991-10-29	Therapeutic guanine esters
EP0366385B1 (fr)	1993-06-09	Dérivés de guanine ayant une activité anti-virale et leurs sels pharmaceutiquement acceptables
US5079252A (en)	1992-01-07	Therapeutic compounds
US5318974A (en)	1994-06-07	Antiviral compounds
IE80513B1 (en)	1998-08-26	Therapeutic nucleosides
HK1012339B (en)	2000-04-07	2-(2-amino-1, 6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives
HK1012339A1 (en)	1999-07-30	2-(2-amino-1, 6-dihydro-6-oxo-purin-9-yl)methoxy-1, 3-propanediol derivatives